Asset Details
Do you wish to reserve the book?
Recent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Recent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer
Do you wish to request the book?
Recent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Recent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer
2026
Overview
Lung cancer (LC) remains the leading cause of cancer-related deaths globally. Conventional therapeutic strategies, including surgery, radiotherapy, and chemotherapy, are often hampered by limitations such as poor tumor selectivity, low bioavailability, and severe systemic toxicity, which compromise treatment efficacy. Nanocarriers are colloidal formulations characterized by abundant porosity and unique physicochemical properties, such as tunable size, high specific surface area, and stimuli-responsiveness. Nanocarrier-based drug delivery systems (NDDSs) have emerged as a promising solution to enable targeted delivery, controlled drug release, and theranostics. This review discusses the advantages, limitations, and clinical translation of three major classes of nanodelivery systems for LC therapy: organic, inorganic, and inorganic-organic hybrid nanosystems. Organic systems are characterized by high biocompatibility and versatile drug-loading capacity, whereas inorganic counterparts provide distinctive optical or magnetic functionalities that enable imaging and synergistic therapy. Hybrid designs integrate both material classes to improve stability and therapeutic performance. Future research is expected to focus on optimizing inhalation strategies for deep lung deposition, developing multi-targeted biomimetic carriers, advancing theranostic platforms, and employing computational tools to accelerate nanocarrier design and clinical translation. This review aims to offer critical perspectives on the development and clinical implementation of nanomedicines for LC.
Publisher
Dove Press,Dove Medical Press
Subject
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - chemistry
/ Drug Delivery Systems - methods
/ Humans
/ Inorganic Nano-delivery systems
/ Inorganic-organic hybrid Nano-delivery systems
/ Lung Neoplasms - drug therapy
/ NDDSs
/ Organic Nano-delivery systems
/ Review
